结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展

摘要/Abstract

中图分类号:

R749.1⁺6

唐静仪, 余群, 刘军. 结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展[J]. 诊断学理论与实践, 2022, 21(01): 12-17.

参考文献43

[1]	Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer′s disease: revising the NINCDS-ADRDA criteria[J]. Lancet Neurol, 2007, 6(8):734-746. doi:10.1016/S1474-4422(07)70178-3pmid:17616482
[2]	Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria[J]. Lancet Neurol, 2014, 13(6):614-629. doi:10.1016/S1474-4422(14)70090-0pmid:24849862
[3]	Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer′s disease[J]. Alzheimers Dement, 2018, 14(4):535-562. doi:10.1016/j.jalz.2018.02.018 URL
[4]	Pontecorvo MJ, Devous MD Sr, Navitsky M, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition[J]. Brain, 2017, 140(3):748-763. doi:10.1093/brain/aww334pmid:28077397
[5]	Marcone A, Garibotto V, Moresco RM, et al. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer′s disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis[J]. J Alzheimers Dis, 2012, 31(2):387-399. doi:10.3233/JAD-2012-111748 URL
[6]	Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer′s disease: recommendations of the International Working Group[J]. Lancet Neurol, 2021, 20(6):484-496. doi:10.1016/S1474-4422(21)00066-1pmid:33933186
[7]	Shen L, Saykin AJ, Kim S, et al. Comparison of manual and automated determination of hippocampal volumes in MCI and early AD[J]. Brain Imaging Behav, 2010, 4(1):86-95. doi:10.1007/s11682-010-9088-xpmid:20454594
[8]	Brewer JB, Magda S, Airriess C, et al. Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease[J]. AJNR Am J Neuroradiol, 2009, 30(3):578-580. doi:10.3174/ajnr.A1402 URL
[9]	Ahdidan J, Raji CA, DeYoe EA, et al. Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging[J]. J Alzheimers Dis, 2016, 49(3):723-732. doi:10.3233/JAD-150559pmid:26484924
[10]	Abrigo J, Shi L, Luo Y, et al. Standardization of hippocampus volumetry using automated brain structure volumetry tool for an initial Alzheimer′s disease imaging biomarker[J]. Acta Radiol, 2019, 60(6):769-776. doi:10.1177/0284185118795327pmid:30185071
[11]	Rathore S, Habes M, Iftikhar MA, et al. A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer′s disease and its prodromal stages[J]. Neuroimage, 2017, 155:530-548. doi:S1053-8119(17)30282-3pmid:28414186
[12]	Hill DLG, Schwarz AJ, Isaac M, et al. Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer′s disease[J]. Alzheimers Dement, 2014, 10(4):421-429,e3. doi:10.1016/j.jalz.2013.07.003 URL
[13]	Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer′s pathological cascade[J]. Lancet Neurol, 2010, 9(1):119-128. doi:10.1016/S1474-4422(09)70299-6 URL
[14]	Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer′s disease[J]. Brain, 2009, 132(Pt 8):2048-2057. doi:10.1093/brain/awp123pmid:19460794
[15]	Colliot O, Chételat G, Chupin M, et al. Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus[J]. Radiology, 2008, 248(1):194-201. doi:10.1148/radiol.2481070876 URL
[16]	Fleisher AS, Sun S, Taylor C, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment[J]. Neurology, 2008, 70(3):191-199. doi:10.1212/01.wnl.0000287091.57376.65pmid:18195264
[17]	McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment[J]. Radiology, 2009, 251(1):195-205. doi:10.1148/radiol.2511080924pmid:19201945
[18]	Sarica A, Vasta R, Novellino F, et al. MRI Asymmetry Index of Hippocampal Subfields Increases Through the Continuum From the Mild Cognitive Impairment to the Alzheimer′s Disease[J]. Front Neurosci, 2018, 12:576. doi:10.3389/fnins.2018.00576 URL
[19]	Yue L, Wang T, Wang J, et al. Asymmetry of Hippocampus and Amygdala Defect in Subjective Cognitive Decline Among the Community Dwelling Chinese[J]. Front Psychiatry, 2018, 9:226.
[20]	de Flores R, La Joie R, Chételat G. Structural imaging of hippocampal subfields in healthy aging and Alzheimer′s disease[J]. Neuroscience, 2015, 309:29-50. doi:10.1016/j.neuroscience.2015.08.033pmid:26306871
[21]	Dong M, Xie L, Das SR, et al. DeepAtrophy: Teaching a neural network to detect progressive changes in longitudinal MRI of the hippocampal region in Alzheimer′s disease[J]. Neuroimage, 2021, 243:118514. doi:10.1016/j.neuroimage.2021.118514 URL
[22]	Sørensen L, Igel C, Liv Hansen N, et al. Early detection of Alzheimer′s disease using MRI hippocampal texture[J]. Hum Brain Mapp, 2016, 37(3):1148-1161. doi:10.1002/hbm.23091pmid:26686837
[23]	Zhao K, Ding Y, Han Y, et al. Independent and reproducible hippocampal radiomic biomarkers for multisite Alzheimer′s disease diagnosis, longitudinal progress and biological basis[J]. Science Bulletin, 2020, 65(13):1103-1113. doi:10.1016/j.scib.2020.04.003 URL
[24]	Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes[J]. Acta Neuropathol, 1991, 82(4):239-259. doi:10.1007/BF00308809pmid:1759558
[25]	de Toledo-Morrell L, Goncharova I, Dickerson B, et al. From healthy aging to early Alzheimer′s disease: in vivo detection of entorhinal cortex atrophy[J]. Ann N Y Acad Sci, 2000, 911:240-253. doi:10.1111/j.1749-6632.2000.tb06730.x URL
[26]	Ryu SY, Lim EY, Na S, et al. Hippocampal and entorhinal structures in subjective memory impairment: a combined MRI volumetric and DTI study[J]. Int Psychogeriatr, 2017, 29(5):785-792. doi:10.1017/S1041610216002349 URL
[27]	Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease[J]. Neurology, 2007, 68(11):828-836. pmid:17353470
[28]	deToledo-Morrell L, Stoub TR, Bulgakova M, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD[J]. Neurobiol Aging, 2004, 25(9):1197-1203. pmid:15312965
[29]	Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD[J]. Neurology, 2002, 58(8):1188-1196. pmid:11971085
[30]	Stoub TR, Rogalski EJ, Leurgans S, et al. Rate of entorhinal and hippocampal atrophy in incipient and mild AD: relation to memory function[J]. Neurobiol Aging, 2010, 31(7):1089-1098. doi:10.1016/j.neurobiolaging.2008.08.003pmid:18809228
[31]	Du AT, Schuff N, Kramer JH, et al. Higher atrophy rate of entorhinal cortex than hippocampus in AD[J]. Neurology, 2004, 62(3):422-427. doi:10.1212/01.WNL.0000106462.72282.90 URL
[32]	Nikolenko VN, Oganesyan MV, Rizaeva NA, et al. Amygdala: Neuroanatomical and Morphophysiological Features in Terms of Neurological and Neurodegenerative Diseases[J]. Brain Sci, 2020, 10(8):502. doi:10.3390/brainsci10080502 URL
[33]	Basso M, Yang J, Warren L, et al. Volumetry of amygdala and hippocampus and memory performance in Alzheimer′s disease[J]. Psychiatry Res, 2006, 146(3):251-261. doi:10.1016/j.pscychresns.2006.01.007 URL
[34]	Basso M, Gelernter J, Yang J, et al. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer′s disease[J]. Neurobiol Aging, 2006, 27(10):1416-1424. doi:10.1016/j.neurobiolaging.2005.08.002 URL
[35]	Poulin SP, Dautoff R, Morris JC, et al. Amygdala atrophy is prominent in early Alzheimer′s disease and relates to symptom severity[J]. Psychiatry Res, 2011, 194(1):7-13. doi:10.1016/j.pscychresns.2011.06.014 URL
[36]	Barnes J, Whitwell JL, Frost C, et al. Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration[J]. Arch Neurol, 2006, 63(10):1434-1439. doi:10.1001/archneur.63.10.1434 URL
[37]	Cavedo E, Boccardi M, Ganzola R, et al. Local amygdala structural differences with 3T MRI in patients with Alzheimer disease[J]. Neurology, 2011, 76(8):727-733. doi:10.1212/WNL.0b013e31820d62d9pmid:21339500
[38]	Miller MI, Younes L, Ratnanather JT, et al. Amygdalar atrophy in symptomatic Alzheimer′s disease based on diffeomorphometry: the BIOCARD cohort[J]. Neurobiol Aging, 2015, 36(Suppl 1):S3-S10. doi:10.1016/j.neurobiolaging.2014.06.032 URL
[39]	Tang X, Holland D, Dale AM, et al. Baseline shape diffeomorphometry patterns of subcortical and ventricular structures in predicting conversion of mild cognitive impairment to Alzheimer′s disease[J]. J Alzheimers Dis, 2015, 44(2):599-611. doi:10.3233/JAD-141605 URL
[40]	Tang X, Holland D, Dale AM, et al. The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer′s disease[J]. Hum Brain Mapp, 2015, 36(6):2093-2117. doi:10.1002/hbm.22758 URL
[41]	Chincarini A, Bosco P, Calvini P, et al. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer′s disease[J]. Neuroimage, 2011, 58(2):469-480. doi:10.1016/j.neuroimage.2011.05.083pmid:21718788
[42]	Zhao L, Luo Y, Lew D, et al. Risk estimation before progression to mild cognitive impairment and Alzheimer′s disease: an AD resemblance atrophy index[J]. Aging(Albany NY), 2019, 11(16):6217-6236.
[43]	Mai Y, Yu Q, Zhu F, et al. AD Resemblance atrophy index as a diagnostic biomarker for Alzheimer′s disease: a retrospective clinical and biological validation[J]. J Alzheimers Dis, 2021, 79(3):1023-1032. doi:10.3233/JAD-201033 URL

结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献43

相关文章15

编辑推荐

Metrics

本文评价

[1]	何亲羽, 王伟, 陈立芬, 张雪蕾, 董治亚.LHCGR基因突变致家族性男性性早熟2例报告及文献复习[J]. 诊断学理论与实践, 2022, 21(05): 598-605.
[2]	武冬冬, 陈玉辉, 刘芳, 刘银红, 蒋景文.脑小血管疾病合并中枢神经系统退行性疾病机制的研究进展[J]. 诊断学理论与实践, 2022, 21(05): 644-649.
[3]	陈志敏, 何浩岚.艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[4]	沈银忠.《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436.
[5]	陈宏, 沈银忠.人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[6]	何新, 陈慧, 冯炜炜.机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546.
[7]	徐子真, 李擎天, 刘湘帆, 李莉, 李惠, 王也飞, 吴洁敏, 陈宁, 梁璆荔, 陈松立, 戴健敏, 宋珍, 丁磊.实验诊断学在线课程的建立和实践[J]. 诊断学理论与实践, 2022, 21(04): 547-550.
[8]	赵然, 詹维伟, 侯怡卿.计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394.
[9]	郭业兵, 郑金峰.阴道壁胃肠道外间质瘤一例报道并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 405-407.
[10]	王刚, 陈生弟.神经病学的诊断：起源、发展及挑战[J]. 诊断学理论与实践, 2022, 21(01): 1-4.
[11]	李建平, 任汝静, 王刚.阿尔茨海默病的临床诊治进展[J]. 诊断学理论与实践, 2022, 21(01): 18-21.
[12]	付丛会, 徐英, 苏巍, 文静, 刘志芳, 朱倩, 张静怡, 熊泽民, 陈兰兰, 贾杰.新型冠状病毒性肺炎疫情封闭管理期间正念减压疗法对阿尔茨海默病患者情绪障碍及睡眠状况的影响分析[J]. 诊断学理论与实践, 2022, 21(01): 46-51.
[13]	魏文石.直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7.
[14]	付朝伟.阿尔茨海默病重在预防——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 8-11.
[15]	黄沛, 任汝静, 潘昱, 林国珍, 王刚.早发型阿尔茨海默病合并脑淀粉样血管病一例报道[J]. 诊断学理论与实践, 2022, 21(01): 86-89.